RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 39 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 39

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Hospital of Guilin Medical University桂林医学院附属医院GuilinHospital page
  2. Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
  3. Study siteBeijing Tsinghua Changgung Hospital北京清华长庚医院BeijingHospital page
  4. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  5. Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page
  6. Study siteFirst Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院ChongqingHospital page
  7. Study siteFirst Affiliated Hospital of Gannan Medical University赣南医科大学第一附属医院GanzhouHospital page
  8. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  9. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  10. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  11. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  12. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  13. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  14. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  15. Study siteGeneral Hospital of Ningxia Medical University宁夏医科大学总医院YinchuanHospital page
  16. Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
  17. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  18. Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
  19. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  20. Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
  21. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  22. Study siteJilin Cancer Hospital吉林省肿瘤医院ChangchunHospital page
  23. Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
  24. Study siteNanjing Tianyinshan Hospital南京天印山医院NanjingHospital page
  25. Study siteNantong Tumor Hospital南通市肿瘤医院NantongHospital page
  26. Study sitePeking Union Medical College Hospital北京协和医院BeijingHospital page
  27. Study siteRenji Hospital上海交通大学医学院附属仁济医院ShanghaiHospital page
  28. Study siteSecond Affiliated Hospital of Anhui Medical University安徽医科大学第二附属医院HefeiHospital page
  29. Study siteSecond Affiliated Hospital of Nanchang University南昌大学第二附属医院NanchangHospital page
  30. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  31. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  32. Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
  33. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  34. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  35. Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
  36. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  37. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  38. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
  39. Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07327034, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Have received at least one prior PD- (L) 1 inhibitor approved as a single agent or in combination for the treatment of HCC and at least one mTKI approved for the treatment of HCC.

    Inclusion criterion 4

    Non-surgically sterilized male or female patients of childbearing potential must agree to use reliable contraception for at least 2 weeks prior to randomization until 1 month after the last dose of study treatment.

    Inclusion criterion 13

    Previous treatment with selective FGFR4 inhibitors.

    Exclusion criterion 2

    Previous anti-tumor therapy is ≤ 4 weeks from randomization.

    Exclusion criterion 4

    Major surgery within 4 weeks prior to randomization; or any surgical wound infection, dehiscence, or incomplete healing within 2 weeks prior to randomization; Or major surgery is planned during study treatment.

    Exclusion criterion 5

    Toxicities caused by prior chemotherapy, radiotherapy, and other anti-tumor therapies (including immunotherapy) did not recover to ≤ Grade 1 CTCAE v5.0.

    Exclusion criterion 8

  3. ECOG performance status 0 or 1.

    Inclusion criterion 9

  4. At least 1 measurable lesion meeting RECIST v1.1 criteria.

    Inclusion criterion 8

  5. History of second primary malignancies other than HCC within the first 5 years of screening.

    Exclusion criterion 6

    Patients coinfected with HBV and HCV.

    Exclusion criterion 11

    Known acquired immunodeficiency syndrome (AIDS) -associated disease or tested positive for HIV 1/2 antibodies.

    Exclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07327034, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed. Patients should be able and willing to comply with study visits and procedures as per protocol.
  • Patients (male or female) ≥ 18 years of age at the time of signing the informed consent form.
  • Patients with advanced or unresectable HCC confirmed histologically/cytologically or clinically according to the American Association for the Study of Liver Diseases (AASLD) criteria (for patients with cirrhosis).
  • Have received at least one prior PD- (L) 1 inhibitor approved as a single agent or in combination for the treatment of HCC and at least one mTKI approved for the treatment of HCC.
  • BCLC stage B(ineligible for local or radical therapy, or relapse or progression of disease after local therapy or radical therapy) or C.
  • Child-Pugh class A.
  • Positive for FGF19 overexpression.
  • At least 1 measurable lesion meeting RECIST v1.1 criteria.
  • ECOG performance status 0 or 1.
  • Life expectancy ≥ 3 months.
  • Adequate control of blood pressure (BP) at screening.
  • Adequate organ function and bone marrow function.
  • Non-surgically sterilized male or female patients of childbearing potential must agree to use reliable contraception for at least 2 weeks prior to randomization until 1 month after the last dose of study treatment.

Exclusion Criteria:

  • Known allergies or hypersensitivity to any component of the investigational product (ABSK-011 or placebo).
  • Previous treatment with selective FGFR4 inhibitors.
  • Known fibrolamellar HCC, sarcomatous HCC, or mixed hepatocellular carcinoma-cholangiocarcinoma.
  • Previous anti-tumor therapy is ≤ 4 weeks from randomization.
  • Major surgery within 4 weeks prior to randomization; or any surgical wound infection, dehiscence, or incomplete healing within 2 weeks prior to randomization; Or major surgery is planned during study treatment.
  • History of second primary malignancies other than HCC within the first 5 years of screening.
  • Liver tumors as a percentage of whole liver ≥ 50% as judged by the investigator.
  • Toxicities caused by prior chemotherapy, radiotherapy, and other anti-tumor therapies (including immunotherapy) did not recover to ≤ Grade 1 CTCAE v5.0.
  • Imaging revealed HCC involving the main portal vein (Vp4), inferior vena cava, superior vena cava, superior mesenteric vein, or heart.
  • Impaired cardiac function or clinically important heart disease.
  • Patients coinfected with HBV and HCV.
  • Known acquired immunodeficiency syndrome (AIDS) -associated disease or tested positive for HIV 1/2 antibodies.
  • Active or documented gastrointestinal bleeding within 6 months prior to screening.
  • Patients with intractable/uncontrolled pleural or pericardial effusion requiring intervention within 2 weeks prior to randomization and clinically significant ascites.
  • Prior or current hepatic encephalopathy (any grade).
  • Presence of meningeal or central nervous system (CNS) metastases.
  • Previous organ transplant and anti-rejection drug therapy indicated.
  • The factors that significantly affect the absorption of oral drugs.
  • Receipt of P-gp transporter inhibitors or moderate, strong inhibitors or inducers of CYP3A4 within 2 weeks prior to randomization.
  • Any serious acute or chronic infection requiring systemic antibacterial, antifungal, or antiviral therapy within 2 weeks prior to randomization.
  • Patient who cannot be assessed by contrast-enhanced CT and/or MRI due to allergy to computed tomography (CT) and/or magnetic resonance imaging (MRI) contrast media or other contraindications.
  • Any other clinically significant comorbidities may affect the patient's health or safety, affect the signing of informed consent, affect protocol compliance, or interfere with the interpretation of the study results.

Quoted from ClinicalTrials.gov, NCT07327034, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07327034, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07327034